H1N1 News and Research

RSS

Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.

Autoimmune clue to narcolepsy

Researchers have identified immune cells in patients with narcolepsy that react against hypocretin, the lack of which causes the disorder.

20 Dec 2013

Biocryst seeks FDA NDA approval for Peramivir to treat influenza

BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.

20 Dec 2013

New antimicrobial coating prevents infections during cold winter months

With cold and flu season now in full swing, all-natural wellness provider Neutra Corp. (OTCBB: NTRR) is working quickly to deliver a revolutionary new antimicrobial coating that could soon prove to be the best defense against infections and viruses in the most notorious hotspot for the spread of these diseases: the classroom.

11 Dec 2013

ATS Labs offers testing of antimicrobial products for efficacy against H7N9 virus

ATS Labs announced today that they are pleased to offer testing of antimicrobial products for efficacy against avian influenza A (H7N9) virus. Avian influenza A (H7N9) virus, called H7N9 for short, has infected humans in China causing severe respiratory illness.

6 Dec 2013

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).

5 Dec 2013

H1N1 virus killed more people globally than originally believed, confirms study

A research team consisting of more than 60 collaborators in 26 countries has estimated the global death toll from the 2009 outbreak of the H1N1 virus to be 10 times higher than the World Health Organization's count, which was based on laboratory-confirmed cases of this flu. The study, which appears online in PLOS Medicine, suggests that the pandemic virus caused up to 203,000 respiratory deaths around the world.

27 Nov 2013

Pediatrician analyzes management of the 2009 influenza A crisis

With autumn just around the corner and a new flu strain lying in wait for us, the presentation of a study analysing the management of the 2009 influenza A crisis could not, if anything, be better timed.

26 Nov 2013

Researchers show for first time how influenza A viruses infect respiratory cells

Researchers at the University of California, San Diego School of Medicine have shown for the first time how influenza A viruses snip through a protective mucus net to both infect respiratory cells and later cut their way out to infect other cells.

25 Nov 2013

U-M researchers collaborate with MDCH to evaluate statewide influenza vaccination reminder campaign

A new University of Michigan study found that the state immunization registry - the public health database that tracks vaccinations- can be an effective tool to encourage influenza vaccinations during a pandemic.

19 Nov 2013

S2O2 finalizes acquisition of Texas-based sanitation technology innovator

Neutra Corp., a growing provider of all-natural wellness solutions, announced today that its joint venture partner Surface to Air Solutions is finalizing the acquisition of a sanitation technology innovator dedicated to greatly reducing the risk of staph infection in sports.

12 Nov 2013

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever.

11 Nov 2013

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides, Inc. (the "Company") reports that its optimized injectable FluCide® drug candidate was found to be well tolerated in a non-GLP small animal safety/toxicology study. This study is an important step in the drug development pathway for FluCide.

21 Oct 2013

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

...

10 Oct 2013

FMCNA encourages dialysis patients to get vaccinated against flu

With early cases of seasonal flu already being reported in the U.S., Fresenius Medical Care North America (FMCNA), the nation's leading network of dialysis facilities, is strongly encouraging dialysis patients to get flu shots to protect themselves against this common infectious disease.

9 Oct 2013

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

A new way to attack flu viruses is taking shape in laboratories at Rutgers University, where scientists have identified chemical agents that block the virus's ability to replicate itself in cell culture.

4 Oct 2013

University of Maryland receives renewed NIH funding for vaccine research

The University of Maryland School of Medicine's Center for Vaccine Development (CVD) has successfully competed for and received a renewed contract to conduct basic research and clinical studies of vaccines, diagnostics, and therapeutics. Support for this work to combat existing and emerging infectious diseases is provided by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

27 Sep 2013

VVRP receives contract from NIH to continue its work as Vaccine and Treatment Evaluation Units

The Vanderbilt Vaccine Research Program (VVRP) has received a contract from the National Institutes of Health (NIH) to continue its work as one of the nation's Vaccine and Treatment Evaluation Units (VTEU).

27 Sep 2013

Group Health helps protect public from infectious diseases through nationwide network

A nationwide group of institutions that conducts clinical trials of promising candidate vaccines and therapies for infectious diseases, known as the Vaccine and Treatment Evaluation Units (VTEUs), has been awarded nine contracts to strengthen and broaden the scope of its research. Group Health Research Institute is one of these institutions.

27 Sep 2013

Researchers find reassuring evidence of H1N1 influenza vaccine's safety during pregnancy

Researchers from Boston University's Slone Epidemiology Center and UC San Diego, in collaboration with the American Academy of Allergy Asthma and Immunology, have found 'reassuring' evidence of the H1N1 influenza vaccine's safety during pregnancy.

24 Sep 2013

EcoHealth Alliance to study land use alteration in disease emergence, climate change in Asia

EcoHealth Alliance, a nonprofit organization that focuses on local conservation and global health issues, announced the award of a three-year, $2 million award to address land use alteration as a significant driver of both disease emergence and climate change in Asia.

24 Sep 2013

H1N1 News and Research

Autoimmune clue to narcolepsy

Biocryst seeks FDA NDA approval for Peramivir to treat influenza

New antimicrobial coating prevents infections during cold winter months

ATS Labs offers testing of antimicrobial products for efficacy against H7N9 virus

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

H1N1 virus killed more people globally than originally believed, confirms study

Pediatrician analyzes management of the 2009 influenza A crisis

Researchers show for first time how influenza A viruses infect respiratory cells

U-M researchers collaborate with MDCH to evaluate statewide influenza vaccination reminder campaign

S2O2 finalizes acquisition of Texas-based sanitation technology innovator

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

FMCNA encourages dialysis patients to get vaccinated against flu

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

University of Maryland receives renewed NIH funding for vaccine research

VVRP receives contract from NIH to continue its work as Vaccine and Treatment Evaluation Units

Group Health helps protect public from infectious diseases through nationwide network

Researchers find reassuring evidence of H1N1 influenza vaccine's safety during pregnancy

EcoHealth Alliance to study land use alteration in disease emergence, climate change in Asia

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News